A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of SSS55 Injection in Healthy Subjects in China
Latest Information Update: 23 Jul 2025
At a glance
- Drugs SSS 55 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
Most Recent Events
- 23 Jul 2025 New trial record